Clicky

Cyclerion Therapeutics, Inc.(CYCN)

Description: Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.


Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Central Nervous System Disease Orphan Disease Cardiomyopathy Sickle Cell Disease Lung Diseases

Home Page: www.cyclerion.com

CYCN Technical Analysis

245 First Street
Cambridge, MA 02142
United States
Phone: 857 327 8778


Officers

Name Title
Dr. Peter M. Hecht Ph.D. CEO & Director
Ms. Cheryl Gault Chief Operating Officer
Ms. Anjeza Gjino CFO & Corp. Sec.
Dr. Todd Milne Ph.D. Sr. VP of External Innovation
Ms. Jessica Rennekamp Associate Director of Corp. Communications
Mr. Christopher Winrow Ph.D. Sr. Director of Clinical Devel. & Neuroscience Program Lead
Ms. Jennifer Chickering Ph.D. Sr. Director of Clinical Strategy

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.7109
Price-to-Sales TTM: 17.4285
IPO Date: 2019-04-02
Fiscal Year End: December
Full Time Employees: 32
Back to stocks